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Acute myeloid leukemia (AML) is a molecularly complex disease characterized by heterogeneous tumor genetic profiles
and involving numerous pathogenic mechanisms and pathways. Integration of molecular data types across multiple patient
cohorts may advance current genetic approaches for improved subclassification and understanding of the biology of the
disease. Here, we analyzed genome-wide DNAmethylation in 649 AML patients using Illumina arrays and identified a con-
figuration of 13 subtypes (termed “epitypes”) using unbiased clustering. Integration of genetic data revealed that most epi-
types were associated with a certain recurrent mutation (or combination) in a majority of patients, yet other epitypes were
largely independent. Epitypes showed developmental blockage at discrete stages of myeloid differentiation, revealing epi-
types that retain arrested hematopoietic stem-cell-like phenotypes. Detailed analyses of DNA methylation patterns identi-
fied unique patterns of aberrant hyper- and hypomethylation among epitypes, with variable involvement of transcription
factors influencing promoter, enhancer, and repressed regions. Patients in epitypes with stem-cell-like methylation features
showed inferior overall survival along with up-regulated stem cell gene expression signatures. We further identified a DNA
methylation signature involving STAT motifs associated with FLT3-ITD mutations. Finally, DNA methylation signatures
were stable at relapse for the large majority of patients, and rare epitype switching accompanied loss of the dominant epi-
type mutations and reversion to stem-cell-like methylation patterns. These results show that DNA methylation-based
classification integrates important molecular features of AML to reveal the diverse pathogenic and biological aspects of
the disease.
[Supplemental material is available for this article.]
Acute myeloid leukemia (AML) is a clinically and molecularly het-
erogeneous disease. Recurrent genetic aberrations, such as chro-
mosomal rearrangements and gene mutations, primarily form
the basis of our current understanding of pathogenesis and are
used for patient classification (Lowenberg et al. 1999; Döhner
et al. 2010, 2017; The Cancer Genome Atlas Research Network
2013). AML has a low level of genetic aberrations relative to other
cancers, but several recurrent aberrations are significantly associat-
ed with prognosis and to tumor cell phenotypes. However, genetic
markers do not completely explain the range of phenotypes ob-
served in tumor cells and disease outcomes.
Efforts have been made to classify AML based on the pheno-
type rather than the genotype in the form of morphology or gene
expression (Bennett et al. 1982; Mrózek et al. 2009; Ng et al. 2016).
AML arises from cells developing from hematopoietic stem and
progenitor cells (HSPCs) into a wide range of developmental phe-
notypes within the myeloid lineage, and developmental arrest is a
key aspect of AML pathogenesis. Epigenetic mechanisms are
central to cellular differentiation by governing the control ex-
pression of key developmental gene expression programs. DNA
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methylation, the addition of amethyl group to the 5′ carbon of cy-
tosines, is the most broadly studied epigenetic mark. Differential
DNA methylation patterns among AML patients has been used
to classify patients with varying results identifying between two
and 16 subgroups depending on the study design (Bullinger
et al. 2010; Figueroa et al. 2010; Melnick 2010; Glass et al. 2017).
Many of these subgroups showed associations with genetic aberra-
tions but others represented novel subgroups. Decoding altered ge-
nome-wide DNA methylation patterns can provide insight into
novel disease-relevant pathways by association to global chroma-
tin states and enrichment of genomic features. DNA methylation
is an attractive biomarker owing to its stability and has been effec-
tively used in multiple cancers to guide therapy (Koch et al. 2018).
Because of the high degree of heterogeneity in AML, we
sought to assemble a large cohort of AML samples to uncover
the breadth of distinct genome-wide DNA methylation states
and to use this classification structure as a basis for a novel inves-
tigation of aberrant disease pathways. Here, we analyzed ge-
nome-wide DNA methylation profiles from well-characterized
AML samples from the Beat AMLproject combinedwith published
data, compiling the largest number ofmethylation profiles studied
to date.We used anunbiased clustering approach to define distinct
subtypes of AML patients and integration with genomic and gene
expression data uncovered that each subtype is associated with a
unique combination of developmental and disease-specific fea-
tures. Our findings highlight prevalent, subtype-specific activa-
tion of inflammatory pathways as a key mechanism uniting
epigenetic, expression and genetic features with poor survival in
AML.
Results
Classification of AML patients into distinct epitypes using
genome-wide DNA methylation
AMLpatients were classified in an unbiased fashion byDNAmeth-
ylation patterns using samples from newly diagnosed patients ob-
tained from the Beat AMLConsortium (n=226) (Tyner et al. 2018)
and the Ohio State University (OSU) n=27, combined with TCGA
(n=190) (The Cancer Genome Atlas Research Network 2013) and
five other independent studies comprising n= 206 patients
(Schmutz et al. 2013; Leonard et al. 2014; Jung et al. 2015; Ferreira
et al. 2016; Eisfeld et al. 2017; Qu et al. 2017) for a total of n=649
patients. DNAmethylation was interrogated by Illuminamethyla-
tion arrays, which provide the DNA methylation levels of CpG
dinucleotides primarily in promoter and regulatory regions (Bibi-
kova et al. 2011).We reduced the data based on overall variance us-
ing the 500most variable probes for cluster analysis and performed
unsupervised k-medoids-based clustering. The total number of
groups (k) was determined using the Auer-Gervini method (Auer
and Gervini 2008; Wang et al. 2018) that uncovered a minimum
of 11 informative principal components (Supplemental Fig. S1A).
By performing clustering and subsequent silhouette analyses
with increasing k from 11, we determined the optimal group num-
ber to be 13 (Supplemental Fig. S1B,C). We termed these clusters
AML DNA methylation epitypes 1–13 (E1–E13). All epitypes
comprised samples from multiple studies (median=5, range =
3–8). Epitype classification remained largely stable upon varying
the number of most variable probes used, with ∼90% sample as-
signmentsunchanged andvariation in epitype assignmentprimar-
ily restricted within E5,E6 and E11–E13 (Supplemental Fig. S1D).
Although sample purity from publicly available sources was not
uniformly available, tumor cell content inferred from somatic mu-
tation data revealed similar sample purity levels across epitypes
(Supplemental Fig. S1E). Hierarchical clustering revealed three
primary clusters (superclusters) each containing 3–5 distinct
DNA methylation epitypes (Fig. 1A). Owing to the high degree
of complexity of epitype-specific patterns, t-distributed stochastic
neighbor embedding (t-SNE) plots were used for subsequent visu-
alization of epitypes and largely agreed with k-medoids-based clus-
tering (Fig. 1B). Several CpGs in this signature were proximal to
genes implicated in AML pathogenesis, such as MEIS1 and several
within the HOXB locus (Supplemental Table S1; Ferreira et al.
2016). However, the majority of the CpGs composing the epityp-
ing signature were located in loci with undescribed associations to
AML.
Epitypes frequently associate with genetic aberrations
To explore the underlying basis of distinct epitypes, we first con-
sidered the relationship to recurrent genetic aberrations.We found
associations between epitypes and common genetic aberrations
consistent with past studies (Figueroa et al. 2010; Glass et al.
2017); however, we found that this linkage was not universal
(Fig. 1C; Supplemental Table S2). Four epitypes were enriched for
alterations in key myeloid transcription factors (TFs): E1–E3 were
enriched for the TF fusions PML-RARA, inv(16)/CBFB, AML-ETO,
respectively, and E4 was enriched forCEBPAmutations. These epi-
types showed the highest association of genetic aberrations (Fig.
1C). Epitypes E1–E4 together formed a distinct supercluster (Fig.
1A) with dominant, epitype-defining genetic aberrations known
to result in arrest of myeloid development and associate with fa-
vorable outcomes (Speck and Gilliland 2002; Pabst and Mueller
2007; De Braekeleer et al. 2014). Epitypes 5 and 6 were enriched
in a variety of chromosomal rearrangements generating fusions in-
volving KMT2A (previously known as MLL) on 11q23. Multiple
KMT2A fusion partners have been described in acute leukemias
(Winters and Bernt 2017), and we observed common AML fusion
partners in both epitypes. Epitypes E7–E10 were strongly enriched
for cytogenetically normal genotypes carrying mutations in the
NPM1 gene. Epitype 8 was enriched for NPM1 mutations alone,
whereas E7, E9, and E10were enriched forNPM1mutations in con-
junction with DNMT3A, TET2, and IDH1/2mutations, respective-
ly. E11–E13 formed a patient supercluster with relative epigenetic
similarity among patterns (Fig. 1D). E11 was enriched in IDH1/2
mutations lacking accompanying NPM1 mutations. Epitypes E12
and E13 lacked a consistent mutation pattern involving amajority
of samples, yet retained mutations associated with genomic insta-
bility, such asTP53mutations and complex karyotype, in aminor-
ity of samples. These results show that there is a close association
between recurrent genetic aberrations in many AML epitypes,
yet others lack a dominant, epitype-defining genotype. In addi-
tion, many samples lack the dominant mutation within a particu-
lar epitype (Fig. 1D), indicating that other cellular events may
converge within epitypes to phenocopy the impact on the epige-
nome, termed “epiphenocopy” events.
Differences between differentiation states reveal nonmutational
features of epitypes
Unlike identifying somatic mutations from germline sequences,
all cell types have distinct epigenetic patterns, thus patterns origi-
nating from normal counterparts must be accounted for when de-
termining tumor cell–specific epigenetic changes. We have




events in chronic lymphocytic leukemia (CLL) (Oakes et al. 2016).
AML is known to display a wide range of hematopoietic differenti-
ation states, from undifferentiated, stem-cell-like phenotypes, to
differentiated mature cells of the myeloid lineage (Bennett et al.
1982; Griffin et al. 1983). In addition, some AML cells retain
immunophenotypic features of granulocytic, erythrocytic, or lym-
phocytic lineages (Bradstock et al. 1989; Macedo et al. 1995;
Matutes et al. 1997). To clearly identify AML epitype-specific
DNAmethylation events, we first expanded our analysis to include
all CpGs measured across all samples (n=426,862). We generated
Illumina array DNA methylation profiles of sorted hematopoietic
populations and combined with publicly available sources (Rein-
ius et al. 2012; The Cancer Genome Atlas Research Network
2013; Jung et al. 2015; Qu et al. 2017). We generated a DNAmeth-
ylation signature that encompasses normal hematopoietic devel-
opment by assembling a probe set of differential methylation
between each subpopulation andHSPC. This signature recapitulat-
ed the branches of the hematopoietic lineages (Supplemental Fig.
S2A). Investigation of this signature together with all AML samples
revealed that the largest proportion of the variation (principal
component 1 [PC1]) among AML samples occurred between
HSPC/myeloid progenitors and mature myeloid cells as expected
(Fig. 2A, left). Lymphocytes were positioned on the side of PC1
with the myeloid progenitors, indicating that PC1 relates to mye-
loid-specific development. PC2 primarily related to a lymphoid-
dominant signature distinct from the vast majority of AML sam-
ples. PC3 largely separated somemyeloid progenitors fromHSPCs,
as well as granulocytes frommonocytes and macrophages, reveal-
ing that AMLs were more similar to monocytes/macrophages than
granulocytes, and, on the progenitor side, are more similar to
HSPC than other progenitors, such as CMP and MEP (Fig. 2A,
right). Taken together, this analysis supports that AMLDNAmeth-
ylation states generally occur between HSPCs and monocytes/
macrophages. Indeed, GMPs are a known intermediate transition-
al subtype between progenitors andmaturemyeloid cells andwere
located centrally in PC1. We further consolidated the develop-
mental signature to the 5000 most differentially methylated
probes between HSPC and monocyte samples. Using this signa-
ture, we observed that AML epitypes occupy specific ranges within
the HSPC to monocyte developmental spectrum (Fig. 2B). E11,
E12, and E13 fell closer to HSPCs, with E11 (IDH1/2) generally
less differentiated than HSPCs. E5 (KMT2A) and E7 (NPM1
+DNMT3A) fell closer to monocytes, with some samples showing
further differentiation toward macrophages, likely caused by tu-
mor-specific methylation changes at developmentally regulated
CpGs. The French-American-British (FAB) classification is a mor-
phological assessment incorporating the differentiation stage of
AML cells that has historically been used as a prognostic marker
(Bennett et al. 1982). Comparing FAB classifications across epi-
types with available annotation (n=247), we observed a discrete
pattern across epitypes, with M0 (undifferentiated leukemia)
scores occurring almost exclusively in E11–E13 and M5 scores
(monocytic leukemia) highly enriched in E5, E7, E8 (Supplemental
Fig. S2B). To further control for potential HSPC-monocyte devel-
opmental signature in AML samples, we investigated the enrich-
ment of transcription factor recognition sequence motifs in
regions displaying altered methylation in monocytes versus
HSPCs. Several TF motifs were highly enriched in monocyte-
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Figure 1. Unsupervised clustering of 649 AML samples using DNA methylation and relationship with genetic mutations. (A) Heatmap of the 500 most
variable CpGs across all samples organized by hierarchical clustering. Samples are annotated by epitype assignment using PAM clustering (colors). (B) The
same 500most variable displayed by t-SNE plot. (C) The distribution of themost common recurrent genetic aberrations in AMLwithin the epitypes. Bubble
size represents the percentage of patients within the epitype with the corresponding aberration. (D) Pie charts displaying the frequency of the most com-
mon (dominant mutation/combination) within each epitype.








Figure 2. Assessment of DNA methylation associated with normal myeloid development enables identification of tumor-specific methylation. (A)
Principal component analysis including healthy cell populations (colored) and AML samples (white) using the hematological developmental probe set
(left, principal component [PC] 1 vs. PC2; right, PC1 vs. PC3). (B) Principal component analysis using a probe set of differentially methylated CpGs between
HSPC and monocytes (white), including AML samples (colored by epitype). (Below) Density plot showing the distribution of samples with each epitype
across PC1. (C) Bubble scatterplot of transcription factor motif enrichment in regions hypomethylated in monocytes compared to HSPC. Bubble size cor-
responds to the P-value, and color corresponds to transcription factor family. (D) A representative scatterplot simultaneously visualizing the DNA methyl-
ation differences in monocyte development (HSPCs to monocytes, x-axis) versus AML development using HSPCs as a reference (y-axis). Values represent
average levels within HSPCs,monocytes, and AML epitype. Tumor-specificmethylation changes are categorized as having aberrant hypermethylation (red)
or aberrant hypomethylation (blue), separately from changes occurring in parallel with normal development (gray) or failing to occur as normally observed
in monocytes (green). (E) Distribution of the tumor-specific methylation changes in each epitype. DNA methylation changes were compared simultane-




specific hypomethylated regions, including CEBP, AP-1, ETS, IRF,
and RUNX TF families (Fig. 2C). Disruption of several members
of these TF families are associated with a block in AML differenti-
ation (Tenen 2003).
We next used changes associated with normal development
to independently identify tumor-specific methylation alterations.
We visualized DNA methylation changes in individual AML epi-
types versus the change that normally occurs in monocyte differ-
entiation using HSPCs as a fixed reference (Fig. 2D). The probes
that change methylation equally in both comparisons represent
normal differentiation, whereas those that diverge from this axis
represent tumor-specific methylation changes. DNA methylation
gains and losses thatwere not observed to involve normal differen-
tiation were termed aberrant hyper- or hypomethylation, respec-
tively. As we consider AML samples that have not reached the
differentiation state ofmaturemyeloid cells to developmentally ar-
rested, hypomethylation events that occurred during normal dif-
ferentiation but failed to occur developmentally in AML were
termed failed (developmental) hypomethylation. Each epitype
displayed unique amounts and proportions of these classes of
methylation change (Fig. 2E). TF-rearranged epitypes (E1–E4) gen-
erally displayed less variation of differentially methylated CpGs
among samples, whereas variationwas higher inmore differentiat-
ed epitypes (E5–E7) (Supplemental Fig. S3). AML epitypes dis-
played variable amounts of failed hypomethylation that closely
correlated with the degree of differentiation in the HSPC-mono-
cyte signature (median PC1) (Supplemental Fig. S2C). Motif en-
richment analyses revealed that all AML epitypes that show
differentiation block (all except E5–E7) involve loss of hypomethy-
lation programming associated with CEBP, SPI1/ETS, RUNX, AP-1,
and IRF TFs, suggesting attenuated activity of these TF pathways
broadly in AML (Supplemental Table S3).
Aberrant DNA methylation patterns reveal disease features
associated with NPM1 mutations
NPM1 is one of themost commonlymutated genes in AML, occur-
ring in 30% of patients and is usually associated with a favorable
outcome except in cases with certain co-occurring mutations
(Papaemmanuil et al. 2016; Tyner et al. 2018). The vast majority
(91%) ofNPM1mutations were found in epitypes E7–E10 (Supple-
mental Table S2) either occurring alone (E8) or frequently in com-
bination with known epigenetic modifier genes DNMT3A (E7),
TET2 (E9), or IDH (E10) (Fig. 1C,D). Although NPM1 by itself is
not described as an epigenetic modifier or regulator, epitype E8 re-
tained among the most aberrant DNA methylation changes, in-
volving both hyper- and hypomethylation (Fig. 2E). This pattern
of aberrant methylation was modulated in combination with oth-
er epigenetic modifiers, skewing toward either hyper- or hypo-
methylation by IDH1/2, TET2, or DNMT3A, respectively (Fig.
3A). Regions of tumor-specific methylation can be used to infer
pathway activation by investigation of TF motif enrichment in se-
lectively hypomethylated regions (Hovestadt et al. 2014). Analysis
of hypomethylated CpGs among E7–E10 revealed that E10 and E8
were largely subsets of the hypomethylation observed in E7, with
E9 demonstrating a subset of uniquely hypomethylated CpGs (Fig.
3B). E7–E10 shared enrichment of RUNX, AP-1, and SPI1motifs in
the aberrant hypomethylated regions, which along with enrich-
ment in failed hypomethylation (Supplemental Table S4), suggests
that activity of these TFs are redirected from patterns of binding
that occur normally (Fig. 3C). E7–E9 shared enrichment for EGR
and TCF sequence motifs in tumor cells only, suggesting aberrant
activation of these pathways in the NPM1 supercluster. E7 and E8
showed enrichment for HOX motifs, consistent with known acti-
vation of HOX genes in NPM1-mutated AML (Spencer et al. 2015).
Epitype E9 displayed selective enrichment for FOXmotifs, suggest-
ing a novel activation of this TF family coincident with TET2 mu-
tations. Despite the combination of DNMT3A and 262 NPM1
mutations, E7 displayed significantly more hypomethylation
than others in the NPM1 supercluster (Fig. 3B), there was little dif-
ference in the TF enrichments, indicating that loss of DNMT3A
function is not associated with specific pathway activation. These
findings suggest that NPM1 loss is a strongmodifier of DNAmeth-
ylation patterns, which amplify methylation changes when com-
bined with the disruption of an epigenetic regulator. Investigation
of aberrant hypermethylation within the NPM1 supercluster re-
vealed that E9 (TET2) and E10 (IDH) displayed higher levels of
largely overlapping hypermethylation, which differed from those
observed in E8 (NPM1 alone) (Fig. 3D). TET2 and IDH1/2 muta-
tions largely act through the same pathway leading to the inhibi-
tion of TET2-dependent demethylation in cancer (Scourzic et al.
2015).
To gain insight into the targeting and functional impact of
hypermethylation, we partitioned the genome into chromatin
states. These states functionally define regions as active, poised,
repressed, or quiescent states in combination with enhancer, pro-
moter, transcribed, and heterochromatic function by a combina-
tion of histone modifications using HSPCs as a reference (Ernst
and Kellis 2010). Hypermethylated regions in E8 (NPM1 alone)
were enriched in regions containing the polycomb repressive his-
tone modification, H3K27me3, and chromatin states containing
this mark, such as poised promoters and enhancers as well as poly-
comb repressed regions (Fig. 3E; Supplemental Table S5). Con-
versely, hypermethylation in E9 (TET2) and E10 (IDH1/2)
showed depletion in polycomb repressed regions and instead
were enriched for active enhancers and regions flanking promot-
ers/transcriptional start sites. Furthermore, hypermethylated en-
hancers in E9 and E10 were selectively enriched with TF motifs
belonging to MEF2 and SPI1/ETS (Fig. 3F; Supplemental Table
S6). Aberrant hypermethylation indicates not only the selective
loss of the normal activity of these TFs in myeloid differentiation,
but a further reversion to a state for these enhancer regions that is
more immature thanHSPC inTET2 and IDH-mutantAML (Schüler
et al. 2008; Will et al. 2015). These findings illustrate commonali-
ties among AML methylation epitypes containing NPM1 muta-
tions (E7–E10) and highlight the distinct differential impact of
mutations in epigenetic modifying enzymes when co-occurring
with NPM1 mutations.
AML epitypes E11–E13 display undifferentiated, HSPC-like features
Epitypes E11–E13 formed a distinct constellation of AML samples
separate from clusters with highly prevalent NPM1 mutations, re-
current chromosomal rearrangements, and other genetic abnor-
malities. Although E11 contained IDH1/2 mutations, E12 and
E13 lacked highly recurrent genetic features (Fig. 1C,D), thus we
further endeavored to uncover unique features associated with
these enigmatic epitypes. E13 revealed little difference in the
DNAmethylation pattern to normal cells, with almost all changes
representing failed hypomethylation (Fig. 4A). DNMT3A was the
most commonly mutated gene in E13, but it was not associated
with methylation loss in this epitype. CpGs displaying failed
hypomethylation in E13 overlap almost entirely with E11 and
E12 (Fig. 4B). These three epitypes were among the most
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undifferentiated in epigenetic developmental analyses (Fig. 2B)
and furthermore contained all samples with undifferentiated
(FABM0) morphology (Supplemental Fig. S2B). Thus, we explored
if these epitypes represent samples showing a stem-cell-like pheno-
type.We first performed t-SNE clustering using the 500-probe sub-
typing signature of all AML samples combined with normal
hematopoietic lineage populations, and we found that normal
cell types cluster in the vicinity of E11–E13, with HSPCs clustering
within E13 (Supplemental Fig. S4A). We next incorporated gene
expression data available in Beat AML and TCGA cohorts to exam-
ine the degree that these epitypes show hematopoietic stem cell
gene expression signatures, such as the LSC17 signature (Ng
et al. 2016). We found that epitypes E11–E13 showed the highest






Figure 3. Analysis of tumor-specific methylation in the NPM1 constellation of epitypes (E7–E10). (A) Scatterplots comparing normal and tumor devel-
opmental methylation changes in E7–E10 highlight differential degrees of failed hypomethylation (green), aberrant hypermethylation (red), or aberrant
hypomethylation (blue). (B) Venn diagram illustrating the numbers and overlap of aberrantly hypomethylated CpGs in E7–E10, with the dominant mu-
tations within each epitype indicated (NPM1 alone or NPM1 plus a modifier mutation). (C) Bubble scatterplot of transcription factor motif enrichment
in regions aberrantly hypomethylated in E7–E10. Bubble size corresponds to the P-value and color corresponds to transcription factor family. (D) Venn
diagram of the aberrant hypermethylation in epitypes E7–E10. (E) Enrichment of aberrantly hypermethylated regions in selected chromatin states defined
using the 15-state ChromHMMmodel in three independent HSPC samples. (F) Bubble scatterplot of transcription factor motif enrichment in regions ab-




were further supported by high overall enrichment in two other
independent stem cell signatures (Supplemental Fig. S4B; Gal
et al. 2006; Gentles et al. 2010). Because stemness has been associ-
ated with poor outcomes (Amadori et al. 1996; Barbaric et al.
2007), we next investigated if patients from E11–E13 showed sig-
nificantly poorer outcomes than other epitypes. We found that
E11–E13 displayed inferior overall survival in both Beat AML and
TCGA cohorts (Fig. 4E), which was also generally observed when
considering individual epitypes (Supplemental Fig. S5). As LSC17
is awell-described prognostic signature of stemness, we next inves-
tigated if stem-cell-like epitypes E11–E13 retained independent
prognostic impact relative to LSC17. Following median dichoto-
mization of LSC17 scores, stem-cell-like epitypes further separated
the overall survival of AML patients in the Beat AML cohort, with a
similar trend observed in TCGA samples (Fig. 4F,G). In multivari-
ate analyses, in the TCGA cohort, E11–E13 retained significance
(P<0.001) and LSC17 did not (Supplemental Table S7).
Further investigation of stem-cell-like epitypes revealed sub-
stantial tumor-specific aberrant hypermethylation in E11 and





Figure 4. AML epitypes E11–E13 display stem-cell-like features. (A) Differential methylation scatterplots of E11–E13 highlight tumor-specific methylation
changes. (B) Venn diagram showing overlap of failed hypomethylation in E11–E13. (C,D) LSC17 gene expression scores in the Beat AML (C) and the TCGA
(D) cohort arranged by epitype. Cohortmedian value is indicated by the dotted line; significance evaluated by ANOVA test followed by comparison of E11–
E13 individually versus E1–E10; adjusted P-values: (∗) P<0.05; (∗∗) P<0.01; (∗∗∗) P<0.001. (E) Kaplan-Meier analysis of overall survival of E11–E13 com-
pared to the other epitypes (E1–E10) in the Beat AML and TCGA cohorts. (F,G) Kaplan-Meier analysis of overall survival of E11–E13 compared to the other
epitypes in the Beat AML and TCGA cohorts following separation into LSC17-high (F) and LSC17-low (G) groups using median dichotomization indicated
above in C and D, respectively.
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of hypermethylated CpGs (Supplemental Fig. S6A). E11 showed
hypermethylation enriched in enhancer regions (Supplemental
Fig. S6B), as expected with prevalent IDH1/2mutations. However,
E12 did not display a dominant mutation or TF enrichment that
potentially explained aberrant hypermethylation. E12 hyperme-
thylation was highly enriched in regions marked by polycomb re-
pressed/poised regions. We next examined differential gene
expression between E11–E13 and healthy HSPCs. We identified
52, 54, and 107 differentially expressed genes in E11, E12, and
E13, respectively (greater than or equal to twofold change, adjust-
ed P≤0.01), with 68/218 genes showing evidence of differential
promoter methylation (Supplemental Table S8). Ingenuity path-
way analysis comparing relative activation of upstream regulators
revealed that the top results in E13were enriched for inflammatory
pathways, including TNF, IL1B, and IFNG (Supplemental Fig.
S6C). We found similar results in E11 and E12, an absence in
E7–E10, and variable enrichment in E1–E6 (Supplemental Fig.
S6D). Hypermethylation of polycomb-marked regions is common-
ly observed in tumors, especially in tu-
mors with activating mutations in
signaling pathways (Gal-Yam et al.
2008; Sproul and Meehan 2013).
Indeed, hematopoietic cells chronically
exposed to inflammatory chemokines
induces hypermethylation of polycomb
regions (Spencer et al. 2017). Combining
observations of DNA methylation and
gene expression changes, our findings
suggest that stem-cell-like epitypes that
lack a dominant driver mutation may
use pro-inflammatory signaling to drive
AML cell proliferation and survival.
FLT3-ITD is linked to a distinct
DNA methylation signature
targeting STAT sites
Pro-inflammatory signaling is common-
ly associated with cancer and often gen-
erated by mutations in tumor cells
(Balkwill and Coussens 2004). In AML,
gain-of-function FLT3-internal tandem
duplication (FLT3-ITD) mutations acti-
vate the JAK/STAT pathway and are asso-
ciated with poor outcomes (Meshinchi
and Appelbaum 2009). FLT3-ITD muta-
tions were spread across several epitypes
(Fig. 1C) and were not enriched in
stem-cell-like epitypes (E11–E13) consis-
tent with past studies (Figueroa et al.
2010; Döhner et al. 2017; Glass et al.
2017). Thus, we next sought to deter-
mine if there was a DNA methylation
signature associated with FLT3-ITD in-
dicative of pro-inflammatory signaling
that was not captured in the most vari-
able methylation signature that defined
the AML epitypes. Because FLT3-ITDmu-
tations were most frequent in the NPM1
supercluster, we compared FLT3-ITD to
FLT3 wild-type samples within E7–E10
only to avoid introducing differences
specific to epitypes with less frequent FLT3 mutations. We identi-
fied 253 probes significantly hypomethylated in FLT3-ITD sam-
ples (20% methylation change, FDR Q<0.01). Motif enrichment
analysis revealed hypomethylated regions were highly enriched
for STAT family sequence motifs, with STAT5A as the top match
(Fig. 5A), consistent with known activation of STAT5A (previously
known as STAT5) in FLT3-ITD AMLs (Choudhary et al. 2007). We
further selected probes in FLT3-ITD-associated hypomethylated
regions that contained a proximal STAT motif to create a probe
set of 101 CpGs that we termed the STAT hypomethylation signa-
ture (SHS) (Supplemental Table S9). We next expanded our analy-
sis to investigate this signature across all AML samples.
Hierarchical clustering in all samples identified a subset of SHS-en-
riched samples we designated as SHS+ AMLs (Fig. 5B). SHS positiv-
ity was not limited to E7–E10 and was found across epitypes (Fig.
5C). SHS positivity was not restricted to FLT3-ITD cases: 73% of
SHS+ were FLT3-ITD, 6% had a FLT3 mutation other than ITD






Figure 5. A hypomethylation signature involving STAT is associated with FLT3-ITD mutations. (A)
Bubble scatterplot of transcription factor motif enrichment in hypomethylated regions in FLT3-ITD-mu-
tated AMLs. Bubble size corresponds to the P-value, and color corresponds to transcription factor family.
(B) Heatmap of the STAT hypomethylation signature with samples arranged by hierarchical clustering.
(C) Distribution of STAT hypomethylation signature-positive (SHS+) samples across AML epitypes. (D)




and 20% of SHS+ cases were devoid of FLT3mutations.We did not
observe statistically significant enrichment of other pathway mu-
tations in SHS+/FLT3 mutation-negative samples. Conversely,
70% of SHS negative cases lacked FLT3 mutations, 14% were
FLT3-ITD, and 17%had a non-ITD FLT3mutation (Fig. 5D). These
results indicate that hypomethylation of STAT binding sites may
occur by other aberrant biological events converging on activation
of the STAT pathway.
DNA methylation patterns at relapse
MostAMLpatients relapse despite achieving a complete remission.
Relapse can involve regrowth of the major clone at diagnosis or
outgrowth of a small resistant tumor cell population that exists
at baseline (Vosberg andGreif 2019). To examine if reexpanded tu-
mor populations at relapse stably maintain or evolve novel DNA
methylation patterns, we analyzed 26 paired diagnosis and relapse
samples using Illumina arrays. Patients achieved a complete remis-
sion of at least 6 mo before relapse, and samples were sort-purified
or had a BLAST percentage >80% to avoid methylation differences
caused by impurity. Using the epityping probe set, 22/26 (85%) of
patient epitypes remained stable at relapse, often producing nearly
identical (overlapping) profiles following clustering (Fig. 6A).
However, four of the patients fell into a different epitype at relapse
than observed at diagnosis. In each of these cases, the relapse
sample migrated to one of the stem-cell-like epitypes (E11–E13),
suggesting the relapse tumor cell population retained a more
immature differentiation state. To determine if the change in the
epigenetic pattern was associated with genetic evolution, samples
were sequenced for 80 commonly recurrent genetic mutations in
AML (Supplemental Table S10; Eisfeld et al. 2017). All patients
showing different epitypes at relapse showed evidence of clonal
evolution, with the relapse sample often losing the dominant epi-
type mutation found in the diagnosis sample (Fig. 6B). Patients
showing the same epitypes at relapse showedminimal genetic var-
iation between time points. To validate these findings, we ob-
tained a second cohort of 41 patients with paired diagnosis/
relapse samples.We observed the same epitype at diagnosis and re-
lapse in 39/41 (95%) patients (Supplemental Fig. S7; Supplemental
Table S11). The two patients that showed a change of epitype
evolved to E13 and showed genetic changes between time points,
consistent with the preceding findings. We next determined if
there were global methylation changes between diagnosis and re-
lapse. We found that many of the samples showed similar epige-
netic patterns at diagnosis and relapse. For the cases that did not
change epitype, on average only 5% of the probes showed a differ-
ence (Δ±20% methylation) compared to 11% for cases that
changed epitype (P=0.0099) (Fig. 6C). We did however observe a
minority of cases that did not change epitype, yet still displayed
a relatively large proportion of altered methylation. These tended
to show gain- or loss-of-signaling pathwaymutations, such as RAS
or FLT3 (Supplemental Table S10), that were not found to be
strongly associated with epitypes. Methylation differences be-
tween diagnosis and relapse in these patients were generally gains
and losses at subclonal (<30%) frequencies, compared to patients
that displayed a change in epitype that showed a higher propor-
tion of clonal (>30%) differences (Fig. 6D). These findings indicate
that DNA methylation patterns are generally stable through ther-
apy, likely owing to overall high stability and homogeneity of
DNAmethylation patterns in tumor cells enabling the clonal pop-
ulation that arises at relapse to be phenotypically similar to the
population at diagnosis. Of the relatively few patients that showed
evolution of DNAmethylation patterns, all (4/4) showed reversion
to an epigenetic pattern consistent with a more stem-cell-like
phenotype.
Discussion
In this study, we used global DNA methylation patterns to gain a
better understanding of the molecular heterogeneity observed in
AML. Using unbiased clustering on a large cohort of AML samples
we identified 13 distinct epitypes. Several epitypes associated with
common AML genetic aberrations and different stages of myeloid
development. Analysis of tumor-specific methylation changes
identified potential mechanisms for tumor development in some
of the less well-defined epitypes. Gene expression analysis identi-
fied epitypes displaying a stem-cell-like phenotype thatwas associ-
ated with overexpression of inflammatory pathways and not
associated with a particular recurrent mutational pattern. We
also identified a separate DNA methylation signature associated
with FLT3-ITD that detects additional patients that use the STAT
inflammatory pathway. Finally, we found that epitypes are stable
between diagnosis and relapse, with themajority of cases retaining
the same epitype and those that change epitype do so with evi-
dence of clonal genetic evolution. Collectively, these findings pro-
vide evidence of AML development based upon acquisition of
developmental pattern of methylation similar to what we have de-
scribed in CLL. Notably, mutations identified in AML are not de-
fining of subgroups when classification is approached in an
unbiased manner.
Prior studies have used DNA methylation patterns to cluster
AML patients using varying technologies and cohort sizes (Bullin-
ger et al. 2010; Figueroa et al. 2010; Melnick 2010; Glass et al.
2017). Studies have found a general relationship of methylation-
based clusters and genetic aberrations (Bullinger et al. 2010; Figue-
roa et al. 2010; Glass et al. 2017), and uncoveredmethylation gains
and losses associated with these aberrations in epigenetic regula-
tors (Glass et al. 2017). In support of these previous studies, we
found tight associations with three of the epigenetic subgroups
and chromosomal rearrangements t(15;17), t(8;21), and inv(16).
Although past studies identified multiple epitypes associated
withCEBPAmutations (Figueroa et al. 2010), we foundCEBPAmu-
tations enriched in a single subgroup. Unlike the previous studies,
we did not find clear differences between the epigenetic patterns
associatedwithmutations in IDH1 and IDH2 (Glass et al. 2017). In-
stead, we found that differences among IDH1/2mutant AMLswere
dependent onwhether an accompanyingNPM1mutationwas pre-
sent or absent (E10 vs. E11, respectively).We found the IDH2 R172
mutation exclusively in E11, consistent with previous studies
showingmutual exclusivitywithNPM1 (Patel et al. 2011). Although
the previous studies indicated some altered DNA methylation pat-
terns associated with NPM1 mutations, we found that the NPM1
mutation has an impact on tumor-specific epigenetic patterns and
is a dominant mutation in 4/13 epitypes. We found the impact
that mutations in known epigenetic regulators DNMT3A, IDH1/2,
or TET2 have on DNAmethylation patterns was lessened or absent
when not co-occurring withNPM1mutations, strongly implicating
a role for NPM1 in epigenetic regulation.
Because the genetic picture of AML is complex (The Cancer
Genome Atlas Research Network 2013), classification of patients
using DNAmethylation patterns may help to describe a simplified
numberof phenotypes and also includepatientswith the sameun-
derlying biology yet lack the recurrent marker mutation. We have
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uncovered that epiphenocopying broadly occurs across the spec-
trum of recurrent mutations in AML. Indeed, phenotypic studies
have revealed CEBPA wild-type AMLs may mimic the biology of
CEBPAmutant AML (Wouters et al. 2007). In our study, epipheno-
copyingwas particularly observed in epitypes we explored inmore
detail (E7–E13), wheremany patients lacked the dominant epitype
mutation. A noteworthy example is E9, which displays an enrich-
ment for TET2 mutations yet half of the cases within this epitype
have wild-type TET2. These epiphenocopies have attained the
same epigenetic pattern through other means, such as potentially






Figure 6. DNA methylation patterns are stable at relapse except in a minority of cases. (A) t-SNE plot of the AML epityping probe set including all AML
samples along with paired diagnosis/relapse samples. The diagnosis and relapse sample (often completely overlapping) are indicated by the same color
within pairs, and those pairs not changing epitype are circled in blue. Red arrows indicate pairs in which the relapse sample changed epitype. Epitypes are
illustrated by standard colors in the inset. (B) Changes in mutant variant allele fraction between diagnosis and relapse in the 4/26 pairs that changed epi-
genetic epitype. (C) The number of probes that change by >20% between diagnosis and relapse; patients that showed change of epigenetic epitype are
displayed separately. (D) Correlation of methylation values from all 426,862 probes at diagnosis and relapse in a representative sample that displayed a




Mutations in epigenetic modifying genes are common in
AML, but characterization of their role in disease development
has been difficult. Mouse models carrying disrupted epigenetic
modifiers, such asDNMT3A,TET2, and IDH1/2, do not alone result
in frank leukemia and require serial transplantation for an overt
AML phenotype to develop (Li et al. 2011; Quivoron et al. 2011;
Sasaki et al. 2012; Celik et al. 2015). The presence of these muta-
tions in asymptomatic individuals, described as clonal hematopoi-
esis of indeterminate potential (Steensma et al. 2015), suggests that
thesemutations occur early in disease development, andmay loos-
en control of the epigenome, allowing for other events to more
readily cause phenotypic reprogramming and disease develop-
ment (Feinberg et al. 2016). Indeed, we observed methyla-
tion losses and gains in E7 (NPM1+DNMT3A) and E9,E10
(NPM1+TET2, IDH1/2) occurred in addition to changes that oc-
curred in NPM1-mutated alone (E8). Although DNMT3A-associat-
ed global methylation loss occurred in conjunction with NPM1
mutations, DNMT3A mutations did not cause hypomethylation
in E13, despite being the most common genetic aberration in
the epitype. This indicates that DNMT3A loss alone does not
induce global DNA hypomethylation, supporting findings in
DNMT3A-null mice (Guryanova et al. 2016). Because we have un-
covered that E13 uses other disease-specific pathways, DNMT3A in
the context of E13 may have primarily played a role in premalig-
nant stages or has a non-DNA methylation-dependent role.
Because DNA methylation is an important factor controlling
gene regulation, in addition to epitype classification, it can also
convey critical aspects of the biology underling AML epitypes.
We found that most AMLs retain developmental DNA methyla-
tion signatures restricted within the development of monocytes
from HSPCs, consistent with results from chromatin accessibility
landscapes performed on a small AML cohort versus a wide variety
of hematopoietic cell types (Corces et al. 2016). AML cells with
granulocytic morphologies may be depleted from samples as a re-
sult of the routine use of ficoll to purify AML cells. We found that
the spread across the developmental axis is associated with the dis-
crete epitypes we identified. Accounting for normal development
enabled us to identify tumor-specific changes to the epigenome,
which in turn inferred disease-specific TF activity and chromatin
states. The changes in E13 relative to HSPCs may represent initial
changes in AML development common to the majority of AMLs,
because only failed hypomethylation was observed without aber-
rant (tumor-specific) changes. Most epitypes are deficient in nor-
mal development similarly involving loss of key developmental
TFs activities to varying degrees. This initial step is likely the block
in differentiation that can be achieved by a variety of mechanisms
and is then followed by some form of proliferation as is suggested
by the two-hit hypothesis of AML development (Lagunas-Rangel
et al. 2017). Our data indicate that NPM1-mutant epitypes univer-
sally show activation of components of RUNX, AP-1, EGR, TCF,
andHOXTF families implicating a variety of upstreampathway ac-
tivation. E9,E10 (NPM1+TET2, IDH1/2) show loss of MEF2, ETS,
and IRF sites focused on enhancer regions, potentially further re-
pressing their normal development.
A common feature of tumor methylomes is hypermethyla-
tion of CpG islands located in gene promoter regions, referred to
as the CpG island hypermethylator phenotype (CIMP) (Toyota
et al. 1999). CIMP subtypes have been described within several tu-
mor types, including colorectal, breast, brain, and gastric cancers,
as well as AML (Roman-Gomez et al. 2005; Weisenberger et al.
2006; Noushmehr et al. 2010; Zouridis et al. 2012; Mack et al.
2014; Kelly et al. 2017). Recent studies have shown that CIMP fre-
quently targets promoters that aremarked by the polycomb repres-
sive mark H3K27me3 in developmental precursors, which
commonly mark poised promoters of developmentally regulated
genes (Bernstein et al. 2006; Ohm et al. 2007; Schlesinger et al.
2007; Widschwendter et al. 2007). In our studies, the association
of aberrant hypermethylation was highly epitype-dependent, be-
ing either largely absent (E5, E7, E13), enriched at enhancers
(E9–E11), or enriched in polycomb repressed and poised regions,
which include CpG islands (E1–E4, E6, E8, E12). CIMP is associat-
ed with prolonged inflammation and stress (Jones and Baylin
2007), and prolonged treatment of HSPCs from healthy donors
with inflammatory cytokines induces hypermethylation of poly-
comb repressed and poised regions (Spencer et al. 2017). Work in
other cancers suggests CIMP tumors may not respond well to
DNA damaging treatments butmay respond better to hypomethy-
lating agents (Mack et al. 2014). Some AML patients with high-risk
genetic markers, such as complex karyotype and TP53 mutations,
have achieved favorable responses with hypomethylating agents
in some patients (Santini and Ossenkoppele 2019). Of interest,
E12 was associated with high-risk genetics, and poor overall sur-
vival. Elevated methylation of polycomb regions may predict fa-
vorable responses to hypomethylating agents in this epitype that
responds poorly to standard chemotherapy. In addition, as we
have shown activation of inflammatory pathways coincident
with polycomb hypermethylation in this epitype, targeting path-
ways such as JAK/STAT may provide additional benefit to these
patients.
Our findings show that DNA methylation is a useful
approach for classifying this genetically heterogeneous, complex
disease, and significantly adds to our understanding of distinct bi-
ological aspects of individual patients. We have shown that epi-
types integrate the majority of highly recurrent mutations,
developmental states, and other phenotypes. Our approach fur-
ther incorporated patients lacking recurrent mutations based on
epigenetic and phenotypic similarity (epiphenocopies). Epitypes
use different pathways, several of which involve activation of in-
flammatory pathways and are associated with poor survival. The
use of epitypes as a biomarker in AML is further supported by
the stability of themethylation patterns throughout disease course
in the vast majority of patients. Future development of a targeted
approach for classification of individual patientswill be vital to un-
lock potential clinical utility of assessing epitypes. Coordinated
evolution of epitype and genetic markers may identify patients
that may benefit from a change in therapy, including hypometh-
ylating and novel agents.
Methods
AML patients and Illumina DNA methylation array data
AML patient samples were collected as part of the Beat AML study
(Tyner et al. 2018), and genomic DNA from 226 bone marrow
samples was obtained at diagnosis along with 13 matched relapse
samples. DNAwas obtained from an additional 27 patients at diag-
nosis with t(v;11) rearrangements and 22 patients sampled at diag-
nosis and relapse from the Leukemia Tissue Bank Shared Resource
at the Ohio State University Comprehensive Cancer Center.
Mononuclear cells from AML samples were isolated using density
gradient separation. Samples with low variant allele frequency
(VAF) of recurrent mutations in myeloid malignancies suggestive
of low tumor cell purity were excluded. Leukemic cells from low
(<80%) BLAST count relapse samples were further purified using
fluorescence-assisted cell sorting (FACS) (BD Biosciences). HSPC
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(CD34+), monocyte (CD14+) populations were isolated using FACS
from bone marrow and peripheral blood. Macrophages were ob-
tained by plating sorted monocyte populations for 14 d. All pa-
tients and donors provided informed consent according to the
Declaration of Helsinki. Genomic DNA was isolated using col-
umn-based preparation (Qiagen). DNA (500 ng) was bisulfite con-
verted using the EZ DNA Methylation Gold Kit (Zymo Research).
The Infinium methylationEPIC assay was carried out following
standard protocol (Illumina) at the Molecular Genetics
Laboratory at the Cincinnati Children’s Hospital. Illumina 450K
Human Methylation Array raw data files for additional AML sam-
ples and sorted healthy populations were obtained from previous-
ly published studies (Kulis et al. 2012; Reinius et al. 2012; The
Cancer Genome Atlas Research Network 2013; Schmutz et al.
2013; Leonard et al. 2014; Jung et al. 2015; Ferreira et al. 2016;
Qu et al. 2017). For the diagnosis/relapse validation cohort, gene
mutation data for 33 patients at diagnosis, remission, and relapse
were obtained fromGreif et al. (2018) alongwith Illuminamethyl-
ation array beta values composing the epityping signature.
Patients were excluded from the study that did not show high fre-
quency tumor-specificmutations (VAF>0.3) at both diagnosis and
relapse. The absence of tumor-specificmutations at remissionwere
also required to indicate clearance of tumor cells following treat-
ment. Data from the Infinium methylationEPIC Array and
Illumina HumanMethylation450 Array were normalized by the
beta mixture quantile (BMIQ) method (Teschendorff et al. 2013)
using the RnBeads analysis software package (Müller et al. 2019).
Only intersecting probes on both platforms were included, and
probes targeting sex chromosomes, non-CpG sites, and single-nu-
cleotide polymorphisms were removed, resulting in a final probe
set of 426,862 probes. Heatmaps, t-SNE plots, and principal com-
ponent analysis plots of combined data were visualized using the
Qlucore Omics Explorer software.
DNA methylation analysis
For clustering analysis, k-medoids-based clustering was used
because of the uneven levels of similarity within clusters. An
Auer-Gervini plot was used to identify theminimumnumber of di-
mensions as the first long step, determined by twice the length of
the average (Wang et al. 2018). k was set using silhouette analysis
(Rousseeuw 1987).
Transcription factor sequence motif enrichment for known
motifs was performed using HOMER software (Heinz et al. 2010).
Windows containing 100 bp of sequence upstream of and down-
stream from selected probes were searched against a background
assembled from the remaining probes that were adjusted for GC
and CpG content as well as a similar methylation distribution in
HSPCs. Motifs with a high degree of similarity were replaced
with a single consensus motif. Chromatin states were defined us-
ing the standard 15-state model previously described using the
ChromHMM algorithm (Ernst et al. 2011). Chromatin states
were defined in three HSPC samples using data available through
the Roadmap Epigenomics Project (Roadmap Epigenomics
Consortiumet al. 2015). Enrichment analysis was performed using
the EpiAnnotator R version 4.02 package (Pageaud et al. 2018;
R Core Team 2021).
To generate a DNA methylation signature that encompasses
normal hematopoietic development we used published methyla-
tion array data from sorted healthy cell populations. We deter-
mined the probes significantly differentially methylated between
each cell population and HSPCs (20% methylation change, FDR
Q<0.01). These individual probe lists were then combined to cre-
ate the hematopoietic development signature (n=28,361). To gen-
erate a normal myeloid development signature, we used the 5000
most variable probes between HSPCs (n =14) and monocytes (n=
15). To identify tumor-specific differences occurring outside of
normal development, we compared changes in individual AML
epitypes versus the change that normally occurs in monocyte dif-
ferentiation using HSPCs as a fixed reference across all analyzed
probes. The methylation values of all probes were averaged within
each AML and normal subtype in scatterplots. The probes that di-
verged from the expected normal development value greater than
a mean of 30% and maintained a false discovery rate (FDR) of Q<
0.05 when considering individual tumor samples were retained
and classified as tumor specific.
Gene expression analysis
Differential gene expression was performed using DESeq2 (Love
et al. 2014) on raw counts were obtained from the Beat AML
Consortium (Tyner et al. 2018). Samples within each epitype
were treated as biological replicates and compared to HSPCs.
Differentially expressed genes were defined as greater than twofold
change and FDRQ<0.01were used. The upstream regulator tool in
the Ingenuity Pathway Analysis software was used to interpret the
results. LSC17 score was calculated using the 17 genes weighted by
regression coefficients as reported in Ng et al. (2016). Beat AML ex-
pression value was calculated from RPKM-normalized RNA-seq
data (Tyner et al. 2018), and TCGA was calculated from
Affymetrix U133 Plus 2 platform (The Cancer Genome Atlas
Research Network 2013). The stem cell signature scores of Gal
et al. (2006) and Gentles et al. (2010) were calculated by the medi-
an expression of the genes in each gene set within each sample us-
ing RPKM-normalized RNA-seq data. ANOVA was used to
determine significant differences between epitypes, followed by
group-specific t-tests adjusting for multiple comparisons using
the Bonferroni method.
Gene mutation analysis
Annotation of genetic mutations and other aberrations were ob-
tained from each respective study where available (n= 511 samples
total) (The Cancer Genome Atlas Research Network 2013;
Schmutz et al. 2013; Jung et al. 2015; Eisfeld et al. 2017; Tyner
et al. 2018). For the analysis of paired diagnosis and relapse sam-
ples from Ohio State University, a panel of 80 genes including
common recurrent AML mutations was targeted using a capture
oligo-based approach followed by sequencing on the MiSeq plat-
form (Illumina) as previously described in Eisfeld et al. (2017).
For paired diagnosis and relapse samples from the Beat AML pro-
ject, mutation data were obtained from published whole exome
data (Tyner et al. 2018).
Data access
All raw and processed sequencing data generated in this studyhave
been submitted to the NCBI Gene Expression Omnibus (GEO;
https://www.ncbi.nlm.nih.gov/geo/) under accession number
GSE159907.
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